NCT07237685Recruiting
Evaluating Atherosclerotic Disease Progression in Patients With Diabetes Mellitus
Evaluating Atherosclerotic Disease Progression in High-Risk Patients With Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
People with type 2 diabetes have a much higher risk of heart disease. One common problem is when the blood vessels that supply the heart become narrowed or blocked by fatty deposits, called plaque. This makes it harder for blood to reach the heart and can lead to serious problems such as chest pain, heart attacks, or even death. This study will follow people with type 2 diabetes who have already had a special heart scan called a coronary CT angiography. This scan takes detailed pictures of the heart's blood vessels. The goal is to understand how heart disease changes over time in people with type 2 diabetes, by looking at repeat scans and other health information. By learning more about how plaque builds up or gets worse, researchers hope to find better ways to identify which patients are most at risk for future heart problems.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 24 Sept 2025
- Start date
- 6 Jun 2025
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Diseases
- Coronary artery disease, Type 2 diabetes
- NCT number
- NCT07237685
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 6 Jun 2025 to the primary completion date, 1 Oct 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of an unstable condition
- Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
Lab values
- Ingeligibility for CCTA acquisition due to severe renal dysfunction (eGFR ≤ 30 mL/min/1.73m²) or known hypersensitivity or contraindication to CT contrast agents
Age
- Baseline (routine care) CCTA performed \< 2 years or \> 5 years before inclusion
Other
- Inability to provide written informed consent
- inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study
Who the study is looking for
- Age over 18 years
- Previous completion of CCTA scan for CAD assessment
- Diagnosed with Type 2 Diabetes and currently receiving glucose lowering treatment
- Sufficient image quality of the CCTA scan (at least 2/3 vessels of sufficient quality for assessment).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam University Medical Centers Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Not yet recruiting |
| Cardiology Centers of the Netherlands Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.